

Supplementary Table 5. Univariate Analysis of Variables Associated with Other Common Pathogen Infections Within 1 Year After RTX

	Overall ¹	Infection ¹	Non-infection ¹	Z/X ²	P
n	110	22	88		
Sex	110			3.6296	0.057 ²
Male	67 (60.91%)	9 (40.91%)	58 (65.91%)		
Female	43 (39.09%)	13 (59.09%)	30 (34.09%)		
Age at onset (mo)	36.40(23.1-63.975)	36.15(20.75-58.875)	36.15(24.975-67.875)	-0.3363	0.739 ³
Age at first RTX(mo)	106.9(77-142.55)	88.05(70.625-108.4)	114.55(78.2-149.375)	-1.7253	0.081 ³
Disease duration before RTX(mo)	54.35(33.1-79.5)	43.3(27.5-62.375)	55.6(34.925-86.975)	-1.6240	0.101 ³
Renal biopsy	110				0.949 ²
No biopsy	73 (66.36%)	15 (68.18%)	58 (65.91%)		
MCD	32 (29.09%)	6 (27.27%)	26 (29.55%)		
FSGS	4 (3.64%)	1 (4.55%)	3 (3.41%)		
Others	1 (0.91%)	0 (0%)	1 (1.14%)		
Baseline regimen	110				0.774 ²
Steroids only	24 (21.82%)	5 (22.73%)	19 (21.59%)		
Steroids + other immunosuppressants	84 (76.36%)	17 (77.27%)	67 (76.14%)		
No immunosuppressant	2 (1.82%)	0 (0%)	2 (2.27%)		
TAC use	110			1.5346	0.144 ²
Yes	70(63.64%)	17(77.27%)	53(60.23%)		
No	40(36.36%)	5(22.73%)	35(39.77%)		
Clinical diagnosis	110			4.0465	0.044 ²
SSNS	68 (61.82%)	9 (40.91%)	59 (67.05%)		
SRNS	42 (38.18%)	13 (59.09%)	29 (32.95%)		
Frequently relapsing	110			0.1304	0.718 ²
Yes	76 (69.09%)	14 (63.64%)	62 (70.45%)		
No	34 (30.91%)	8 (36.36%)	26 (29.55%)		
IVIG use,1 yr pre-RTX	110				0.698 ²
Yes	103(93.64%)	21(95.45%)	82(93.18%)		
No	7(6.36%)	1(4.55%)	6(6.82%)		
Relapse within 1 yr after RTX	110			1.9177	0.166 ²
Yes	17 (15.45%)	6 (27.27%)	11 (12.5%)		
No	93 (84.55%)	16 (72.73%)	77 (87.5%)		

Note: The infection group included patients who experienced at least one episode of common bacterial(excluding M. tuberculosis), atypical pathogen, or viral(excluding EBV, CMV and HBV) infection within 12 months after RTX infusion. The non-infection group included patients without any documented infections during the same period. Abbreviations: RTX, rituximab; SSNS, steroid-sensitive nephrotic syndrome; SRNS, steroid-resistant nephrotic syndrome; MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; IVIG, intravenous immunoglobulin; TAC, tacrolimus.

¹ Data are shown as n (%), mean \pm SD, or median (IQR).

² Pearson's chi-squared test or Fisher's exact test was used for categorical variables, as appropriate.

³ Wilcoxon test.